Literature DB >> 23844816

Mesenchymal stromal cell therapy for cardio renal disorders.

Marlies E J Reinders, Danielle G Leuning, Johan W de Fijter, Martin J Hoogduijn, Ton J Rabelink1.   

Abstract

Chronic kidney disease carries a very high mortality risk, in particular from cardiac diseases. Often heart failure and renal failure coincide, a phenomenon referred to as the cardio renal syndrome. In recent years, it has become clear that not only fibrotic repair but also restoration of damaged kidney and heart can occur and the use of cell therapy has been advanced as a means to activate endogenous repair mechanisms or even to re-introduce repairing tissue. In this perspective, mesenchymal stromal cells are of particular interest, since these cells have both immune modulating and reparative functions and are on the brink of entering the clinical arena. Indeed, MSCs can trigger numerous therapeutic biologic processes that contribute to both renal and cardiac repair; however exact mechanisms of actions are largely unknown. In the present review we have made a critical appraisal of the data available with respect to origin and function of MSCs, and we discuss both preclinical as well as clinical evidence on their therapeutic potential in kidney and heart disease.

Entities:  

Mesh:

Year:  2014        PMID: 23844816     DOI: 10.2174/13816128113199990477

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

Review 1.  Secretion of immunoregulatory cytokines by mesenchymal stem cells.

Authors:  Dobroslav Kyurkchiev; Ivan Bochev; Ekaterina Ivanova-Todorova; Milena Mourdjeva; Tsvetelina Oreshkova; Kalina Belemezova; Stanimir Kyurkchiev
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

2.  Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease.

Authors:  Lei Zhang; Xiang-Yang Zhu; Yu Zhao; Alfonso Eirin; Lei Liu; Christopher M Ferguson; Hui Tang; Amir Lerman; Lilach O Lerman
Journal:  Basic Res Cardiol       Date:  2020-01-14       Impact factor: 17.165

3.  Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease.

Authors:  Alfonso Eirin; Xiang-Yang Zhu; Christopher M Ferguson; Scott M Riester; Andre J van Wijnen; Amir Lerman; Lilach O Lerman
Journal:  Stem Cell Res Ther       Date:  2015-01-19       Impact factor: 6.832

4.  Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts.

Authors:  Evangelia Papadimou; Marina Morigi; Paraskevas Iatropoulos; Christodoulos Xinaris; Susanna Tomasoni; Valentina Benedetti; Lorena Longaretti; Cinzia Rota; Marta Todeschini; Paola Rizzo; Martino Introna; Maria Grazia de Simoni; Giuseppe Remuzzi; Michael S Goligorsky; Ariela Benigni
Journal:  Stem Cell Reports       Date:  2015-03-05       Impact factor: 7.765

5.  Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive In vitro and in a Humanized Allograft Rejection Model.

Authors:  Marieke Roemeling-van Rhijn; Meriem Khairoun; Sander S Korevaar; Ellen Lievers; Danielle G Leuning; Jan Nm Ijzermans; Michiel Gh Betjes; Paul G Genever; Cees van Kooten; Hans Jw de Fijter; Ton J Rabelink; Carla C Baan; Willem Weimar; Helene Roelofs; Martin J Hoogduijn; Marlies E Reinders
Journal:  J Stem Cell Res Ther       Date:  2013-11-25

6.  NK Cells and MSCs: Possible Implications for MSC Therapy in Renal Transplantation.

Authors:  Marlies Ej Reinders; Martin J Hoogduijn
Journal:  J Stem Cell Res Ther       Date:  2014-02-07

7.  Unique regulatory properties of mesangial cells are genetically determined in the rat.

Authors:  Ping-Chin Lai; Ling-Yin Chiu; Prashant Srivastava; Cristina Trento; Francesco Dazzi; Enrico Petretto; H Terence Cook; Jacques Behmoaras
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

8.  Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.

Authors:  Marlies E J Reinders; Geertje J Dreyer; Jonna R Bank; Helene Roelofs; Sebastiaan Heidt; Dave L Roelen; Maarten L Zandvliet; Volkert A L Huurman; Wim E Fibbe; Cees van Kooten; Frans H J Claas; Ton J Rabelink; Johan W de Fijter
Journal:  J Transl Med       Date:  2015-11-04       Impact factor: 5.531

9.  Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.

Authors:  Marlies E J Reinders; Jonna R Bank; Geertje J Dreyer; Helene Roelofs; Sebastian Heidt; Dave L Roelen; Volkert Al Huurman; Jan Lindeman; Cees van Kooten; Frans H J Claas; Wim E Fibbe; Ton J Rabelink; Johan W de Fijter
Journal:  J Transl Med       Date:  2014-12-10       Impact factor: 5.531

10.  The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment.

Authors:  Daniëlle G Leuning; Nick R M Beijer; Nadia A du Fossé; Steven Vermeulen; Ellen Lievers; Cees van Kooten; Ton J Rabelink; Jan de Boer
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.